Dr. Telli's clinical research focuses on breast cancer treatment, particularly in the early disease setting, and survivorship. She has led several clinical trials testing novel therapeutic strategies for the treatment of triple negative and BRCA mutation-associated breast cancers. She has an interest in the cardiotoxicity of novel anti-cancer agents and the prevention of treatment-related cardiac injury in breast cancer patients. Dr. Telli’s Komen-funded research aims at optimizing treatment for triple negative breast cancer patients by identifying genomic instability and immune biomarkers that will help predict which patients are most likely to benefit from platinum-based chemotherapy and spare toxicity for those unlikely to benefit.